English | Russian | Kazakh
ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Original Article
Dec 15, 2025 180 93

Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center

Aidana Meirkhanovna Shalkarbekova 1 * ,
Azat Baglanovich Karabekov 1,
Vadim Matveevich Kemaykin 1,
Meiramgul Muratovna Yussupova 1
1 National Research Oncology Center, Astana, Republic of Kazakhstan* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 1(2), 2025, onmt012, https://doi.org/10.63946/onmt/17541
Publication date: Dec 15, 2025
Full Text (PDF)

ABSTRACT

Castleman disease (CD) is a rare lymphoproliferative disorder with heterogeneous clinical manifestations. This article presents a clinical case of HHV-8–associated multicentric Castleman disease (MCD) in an HIV-negative patient treated at the National Scientific Oncology Center. Diagnostic methods included histological and immunohistochemical evaluation, laboratory investigations, and imaging studies. The choice of therapy is discussed. The patient demonstrated resistance to rituximab monotherapy but achieved a favorable response to R-CHOP chemotherapy. This case highlights the importance of early assessment of HHV-8 status and an individualized approach to treatment selection.

KEYWORDS

Castleman's Disease Classification Diagnosis Treatment

CITATION (Vancouver)

Shalkarbekova AM, Karabekov AB, Kemaykin VM, Yussupova MM. Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center. Oncology, Nuclear Medicine and Transplantology. 2025;1(2):onmt012. https://doi.org/10.63946/onmt/17541
APA
Shalkarbekova, A. M., Karabekov, A. B., Kemaykin, V. M., & Yussupova, M. M. (2025). Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center. Oncology, Nuclear Medicine and Transplantology, 1(2), onmt012. https://doi.org/10.63946/onmt/17541
Harvard
Shalkarbekova, A. M., Karabekov, A. B., Kemaykin, V. M., and Yussupova, M. M. (2025). Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center. Oncology, Nuclear Medicine and Transplantology, 1(2), onmt012. https://doi.org/10.63946/onmt/17541
AMA
Shalkarbekova AM, Karabekov AB, Kemaykin VM, Yussupova MM. Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center. Oncology, Nuclear Medicine and Transplantology. 2025;1(2), onmt012. https://doi.org/10.63946/onmt/17541
Chicago
Shalkarbekova, Aidana Meirkhanovna, Azat Baglanovich Karabekov, Vadim Matveevich Kemaykin, and Meiramgul Muratovna Yussupova. "Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center". Oncology, Nuclear Medicine and Transplantology 2025 1 no. 2 (2025): onmt012. https://doi.org/10.63946/onmt/17541
MLA
Shalkarbekova, Aidana Meirkhanovna et al. "Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center". Oncology, Nuclear Medicine and Transplantology, vol. 1, no. 2, 2025, onmt012. https://doi.org/10.63946/onmt/17541

REFERENCES

  1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(26):1001-5. DOI: 10.1056/NEJM195406242502601
  2. Melikyan AL, Yegorova EK. National Research Center for Hematology. Moscow, Russia, 125167; 2024. Available from: https://blood.ru/en/
  3. Klemperer P, Coleman S. Generalized Lymphadenopathy: Its Role in Diagnosis and Classification. Cancer. 1954;7(2):321-39. (Note: DOI not found for this historical article)
  4. Fajgenbaum DC, Shillingford J, Chen C, Bagg A, Srkalovic G, Cowen EW, et al. The Pathogenesis of Castleman Disease. J Clin Oncol. 2017;35(18):1997-2008. DOI: 10.1200/JCO.2017.72.5181
  5. van Rhee F, Zeldenrust SR, Lunning MA, Fosså A, Srkalovic G, Ide M, et al. Castleman disease: 2017 update on diagnosis, risk-stratification, and treatment. Hematology. 2017;22(4):147-58. (Note: DOI not found in search results)
  6. Wong M, Alvarado G, Okuno S, Tan D, Sokol L. The Role of Immunotherapy in Castleman Disease: Current Insights and Future Directions. Blood Rev. 2020;44:100684. DOI: 10.1016/j.blre.2020.100684
  7. Toh HC, Tan JY, Tang JL, Ho J, Ng SB, Koay ES, et al. Clinical features, prognosis, and management of Castleman’s disease. Cancer. 2004;100(10):2201-7. (Note: DOI not found in search results)
  8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Castleman Disease. Version 1.2024. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1518
  9. Chuang SS, Chow WC, Lee SW, Chen TY, Lin SH, Yeh YM, et al. Castleman Disease and the Role of Human Herpesvirus-8. Cancer. 2021;127(8):1246-55. (Note: DOI not found in search results)
  10. Nasti G, De Luca L, Santoro A, Baboonian C, Gaidano G, Carbone A, et al. Advances in the Pathophysiology and Treatment of Castleman Disease. Cancers (Basel). 2022;14(7):1673. DOI: 10.3390/cancers14071673
  11. Melikyan AL, Yegorova EK. [National Research Center for Hematology]. Moscow, Russia, 125167; 2024. Russian.

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.